Vice President of Academic Affairs & Research Professor of Molecular Pharmacology/Clinical Biochemistry/Medicinal Chemistry/Biomedical Sciences, College of Medicine/Graduate Studies Dean of the College of Graduate Studies
Office: (916) 686 - 7438 Catherine.Yang@cnsu.edu
Dr. Yang is a Professor of Molecular Pharmacology and Clinical Biochemistry at the Department of Basic Science of College of Medicine of California Northstate University (CNU). At CNU she has been overseeing the operation of the new medical education program at CNU for its’ innovative system-based curriculum in the vicinity of a very diverse population in Northern California that medical students can be trained to treat a broad spectrum of diseases and coauthored a medical education article describing the CNUCOM integrated system-based curriculum and its pedagogy published in the AAMC Academic Medicine Journal (2020). And she is currently involved in the special interest group for the Artificial Intelligence in Frontiers of Medical Research & NAIRR national AI initiatives and her AI aided drug modeling generated a prostate cancer drug candidate. She also leads the Institute of Artificial Intelligence in Medical Sciences (IAiMedS).
Dr. Yang has over 25-y teaching experience in five universities in the US in the areas of Medicinal Chemistry, Molecular Pharmacology, Oncology, AI-Aided Drug Design and Clinical Biochemistry with twice awards of wall of fame for being selected as the best professor who impacts their career the most. She also published more than 100 peer-reviewed research articles, several biotechnology & clinical application books, and is an inventor of 10 patented inventions. She has also secured numerous grants from the NIH, NSF, Research Corporation and New Jersey Health Foundation as well as fundings from many corporations and health foundations. She serves on various review boards of federal, private and health foundation funding agencies. She also serves as chairman of board of an education foundation [a non-profit 501 c(3) organization].
Dr. Yang’s research interest centers around the proteolytic regulation in various disease progression stages including cancer. Her drug discovery programs specifically target type 2 diabetes, prostate cancer, leukemia and lung cancer. Dr. Yang’s research has made strong contributions in elucidating mechanisms of tumor progression, and in the development of novel cancer drugs. She has led research groups funded by NIH studying proteolytic regulatory mechanisms in the advanced stages of prostate cancer, lung cancer and leukemia. Her in-depth research on type 2 diabetic metabolic regulation led to a dual function diabetes drug patent. Dr. Yang’s immunological research resulted in an allergy vaccine development that is currently under clinical trials at affiliated clinics. The specific approach of triggering induction of immunologic tolerance to external or autologous allergens, and induction of sensitization to infectious or tumor antigens, with targeted tissue delivery of particles sized to facilitate uptake by specific cell populations, provide unique therapeutic platform for curing advancement stage cancer. She is also engaged in clinical trial studies for her innovative leukemia drug candidate. Dr. Yang’s unique predictive biomarker studies have also spurred a nano-sensor development for an early cancer diagnosis.
Dr. Yang’s current research interest has also grown on medical education. Prior to joining CNU in 2016, Dr. Yang was involved in developing Rowan Cooper Medical School in the areas of curriculum model development and pedagogy, research programs and their facility design as well as hospital affiliations.